<p>在這一週，儘管面臨通脹壓力和地緣政治不確定性，全球市場在穩健的企業盈利和標準普爾 500 指數及納斯達克綜合指數創下歷史新高的背景下展現出韌性。隨着投資者在這些動態條件中進行導航，識別與有利經濟指標相符的高增長科技股可能是把握這一不斷演變的市場潛在機會的關鍵。</p>
<h3>全球十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellego Technologies</td>
<td>28.42%</td>
<td>47.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海華測導航科技</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 741 只股票的完整列表。</p>
<p>讓我們探索篩選結果中的幾個突出選項。</p>
<h2>MLOptic (SHSE:688502)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> MLOptic Corp. 是一家精密光學解決方案公司，在中國和國際上運營，市值為 155.5 億人民幣。</p>
<p><strong>運營：</strong> MLOptic Corp. 的主要收入來源於其電子元件與零部件部門，收入為 5.3414 億人民幣。</p>
<p>MLOptic 展現出強勁的財務表現，2025 年第一季度的淨收入顯著增長，從去年同期的 428 萬人民幣激增至 1664 萬人民幣。這一增長得益於年收入增長 22.4%，超過了中國市場整體 12.4% 的增長率。儘管本季度未進行股票回購，但公司在創新方面的戰略重點通過其研發投資得以體現，這與其收入增長軌跡相一致，並增強了其在科技領域的競爭優勢。該公司維持高質量盈利的能力以及預計年利潤增長 30.1% 使其在高增長科技領域中具備持續發展的良好基礎。</p>
<ul>
<li>點擊探索我們在 MLOptic 健康報告中的詳細發現。</li>
<li>查看 MLOptic 的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688502 截至 2025 年 7 月的盈利和收入增長</p>
<h2>CASTECH (SZSE:002222)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> CASTECH Inc. 專注於晶體元件、精密光學元件和激光設備的研發、生產和銷售，主要在中國，市值為 162.1 億人民幣。</p>
<p><strong>運營：</strong> 該公司的收入主要來自光電行業，收入為 9.0731 億人民幣。</p>
<p>CASTECH 最近被納入深圳證券交易所的關鍵指數，標誌着市場認可度的提高。這與其強勁的財務表現相一致，年收入增長達到 27.3%，顯著超過了中國市場整體 12.4% 的增長率。值得注意的是，盈利年增長率為 34.8%，反映出強大的運營效率和市場需求。公司在研發方面的投入顯示出其對創新的承諾，這對於在競爭激烈的科技環境中維持這一勢頭至關重要。</p>
<ul>
<li>點擊這裏深入瞭解 CASTECH 的綜合健康報告。</li>
<li>通過查看我們的歷史表現報告，獲取 CASTECH 的歷史表現洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002222 截至 2025 年 7 月的盈利和收入增長</p>
<h2>深圳康泰生物製品 (SZSE:300601)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 深圳康泰生物製品有限公司專注於疫苗和生物製品的研發、生產和銷售，市值為 181.7 億人民幣。</p>
<p><strong>運營：</strong> 康泰生物製品主要通過疫苗和生物製品的銷售產生收入。該公司的市值為 181.7 億人民幣。</p>
<p>儘管深圳康泰生物製品在過去一年中面臨挑戰，盈利增長收縮了 76.1%，但仍預計將出現顯著反彈，預計年利潤增長為 38.6%。這與其行業平均下降 17.7% 形成鮮明對比。公司的研發投資仍然至關重要，與其戰略重點相一致，以推動未來的表現。此外，最近通過股息確認的股東支持反映出對其財務健康和回報投資者價值的信心。</p>
<ul>
<li>解鎖我們對深圳康泰生物製品股票分析的全面洞察，查看此健康報告。</li>
<li>通過我們的詳細歷史表現報告評估深圳康泰生物製品的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300601 截至 2025 年 7 月的收入和支出明細</p>
<h2>下一步</h2>
<ul>
<li>深入瞭解我們識別的 741 只全球高增長科技和人工智能股票。</li>
<li>投資了這些股票中的任何一隻？通過 Simply Wall St 簡化您的投資組合管理，並隨時獲取有關您股票的關鍵更新提醒。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受跨越每個大洲的市場情報的免費訪問。</li>
</ul>
<h2>尋找其他投資？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力可觀但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

福晶科技

<p>在強勁的企業盈利和標準普爾 500 指數及納斯達克創下歷史新高的一週，全球市場在通脹和地緣政治不確定性中依然表現出韌性。投資者被鼓勵識別高增長的科技股。值得注意的公司包括 MLOptic、福晶科技和深圳康泰生物製品，它們的收入和盈利均顯示出顯著增長。MLOptic 的收入增長了 22.4%，福晶科技增長了 27.3%，而康泰預計將反彈，利潤增長達到 38.6%。文章強調了研發投資和市場認可對科技行業持續增長的重要性</p>

<p>In a week marked by solid corporate earnings and record highs for the S&amp;P 500 and Nasdaq Composite, global markets have shown resilience despite inflationary pressures and geopolitical uncertainties. As investors navigate these dynamic conditions, identifying high-growth tech stocks that align with favorable economic indicators can be key to capitalizing on potential opportunities in this evolving landscape.</p>
<div class="lb-trans"><p>在這一週，儘管面臨通脹壓力和地緣政治不確定性，全球市場在穩健的企業盈利和標準普爾 500 指數及納斯達克綜合指數創下歷史新高的背景下展現出韌性。隨着投資者在這些動態條件中進行導航，識別與有利經濟指標相符的高增長科技股可能是把握這一不斷演變的市場潛在機會的關鍵。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellego Technologies</td>
<td>28.42%</td>
<td>47.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellego Technologies</td>
<td>28.42%</td>
<td>47.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海華測導航科技</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 741 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 741 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>讓我們探索篩選結果中的幾個突出選項。</p>
</div><h2>MLOptic (SHSE:688502)</h2>
<div class="lb-trans"><h2>MLOptic (SHSE:688502)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> MLOptic Corp. is a precision optical solutions company that operates both in China and internationally, with a market capitalization of CN¥15.55 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MLOptic Corp. 是一家精密光學解決方案公司，在中國和國際上運營，市值為 155.5 億人民幣。</p>
</div><p><strong>Operations:</strong> MLOptic Corp.'s primary revenue stream is from its Electronic Components &amp; Parts segment, generating CN¥534.14 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> MLOptic Corp. 的主要收入來源於其電子元件與零部件部門，收入為 5.3414 億人民幣。</p>
</div><p>MLOptic has demonstrated robust financial performance, with a notable increase in Q1 2025 earnings, where net income surged to CNY 16.64 million from CNY 4.28 million year-over-year. This growth is underpinned by a significant annual revenue increase of 22.4%, outpacing the broader Chinese market's growth rate of 12.4%. Despite not engaging in share repurchases this quarter, the company's strategic focus on innovation is evident from its R&amp;D investments, aligning with its revenue growth trajectory and enhancing its competitive edge in the tech sector. The firm’s ability to maintain high-quality earnings and a forecasted annual profit growth of 30.1% positions it well for sustained advancement within the high-growth tech landscape.</p>
<div class="lb-trans"><p>MLOptic 展現出強勁的財務表現，2025 年第一季度的淨收入顯著增長，從去年同期的 428 萬人民幣激增至 1664 萬人民幣。這一增長得益於年收入增長 22.4%，超過了中國市場整體 12.4% 的增長率。儘管本季度未進行股票回購，但公司在創新方面的戰略重點通過其研發投資得以體現，這與其收入增長軌跡相一致，並增強了其在科技領域的競爭優勢。該公司維持高質量盈利的能力以及預計年利潤增長 30.1% 使其在高增長科技領域中具備持續發展的良好基礎。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in MLOptic's health report.</li>
<li>Examine MLOptic's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 MLOptic 健康報告中的詳細發現。</li>
<li>查看 MLOptic 的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688502 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>SHSE:688502 截至 2025 年 7 月的盈利和收入增長</p>
</div><h2>CASTECH (SZSE:002222)</h2>
<div class="lb-trans"><h2>CASTECH (SZSE:002222)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> CASTECH Inc. focuses on the R&amp;D, production, and sale of crystal components, precision optical components, and laser devices primarily in China with a market capitalization of CN¥16.21 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CASTECH Inc. 專注於晶體元件、精密光學元件和激光設備的研發、生產和銷售，主要在中國，市值為 162.1 億人民幣。</p>
</div><p><strong>Operations:</strong> The company derives its revenue primarily from the optoelectronics industry, generating CN¥907.31 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自光電行業，收入為 9.0731 億人民幣。</p>
</div><p>CASTECH has recently been added to key indices on the Shenzhen Stock Exchange, signaling increased market recognition. This aligns with its robust financial performance, where annual revenue growth stands at 27.3%, significantly outpacing the broader Chinese market's growth rate of 12.4%. Notably, earnings have surged by 34.8% annually, reflecting strong operational efficiency and market demand. The company's commitment to innovation is evident in its R&amp;D investments which are crucial for sustaining this momentum in a competitive tech landscape.</p>
<div class="lb-trans"><p>CASTECH 最近被納入深圳證券交易所的關鍵指數，標誌着市場認可度的提高。這與其強勁的財務表現相一致，年收入增長達到 27.3%，顯著超過了中國市場整體 12.4% 的增長率。值得注意的是，盈利年增長率為 34.8%，反映出強大的運營效率和市場需求。公司在研發方面的投入顯示出其對創新的承諾，這對於在競爭激烈的科技環境中維持這一勢頭至關重要。</p>
</div><ul>
<li>Navigate through the intricacies of CASTECH with our comprehensive health report here.</li>
<li>Gain insights into CASTECH's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 CASTECH 的綜合健康報告。</li>
<li>通過查看我們的歷史表現報告，獲取 CASTECH 的歷史表現洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002222 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:002222 截至 2025 年 7 月的盈利和收入增長</p>
</div><h2>Shenzhen Kangtai Biological Products (SZSE:300601)</h2>
<div class="lb-trans"><h2>深圳康泰生物製品 (SZSE:300601)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shenzhen Kangtai Biological Products Co., Ltd. focuses on the research, development, production, and distribution of vaccines and biological products with a market cap of CN¥18.17 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 深圳康泰生物製品有限公司專注於疫苗和生物製品的研發、生產和銷售，市值為 181.7 億人民幣。</p>
</div><p><strong>Operations:</strong> Kangtai Biological Products generates revenue primarily through the sale of vaccines and biological products. The company operates with a market capitalization of CN¥18.17 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 康泰生物製品主要通過疫苗和生物製品的銷售產生收入。該公司的市值為 181.7 億人民幣。</p>
</div><p>Shenzhen Kangtai Biological Products, despite a challenging year with earnings growth contracting by 76.1%, still forecasts a notable rebound with an expected annual profit growth of 38.6%. This contrasts sharply with its industry's average decline of 17.7%. The company's R&amp;D investments remain pivotal, aligning with its strategic focus on innovation to drive future performance. Additionally, recent shareholder endorsements via dividend affirmations reflect confidence in its financial health and commitment to returning value to investors.</p>
<div class="lb-trans"><p>儘管深圳康泰生物製品在過去一年中面臨挑戰，盈利增長收縮了 76.1%，但仍預計將出現顯著反彈，預計年利潤增長為 38.6%。這與其行業平均下降 17.7% 形成鮮明對比。公司的研發投資仍然至關重要，與其戰略重點相一致，以推動未來的表現。此外，最近通過股息確認的股東支持反映出對其財務健康和回報投資者價值的信心。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Shenzhen Kangtai Biological Products stock in this health report.</li>
<li>Assess Shenzhen Kangtai Biological Products' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對深圳康泰生物製品股票分析的全面洞察，查看此健康報告。</li>
<li>通過我們的詳細歷史表現報告評估深圳康泰生物製品的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300601 Revenue and Expenses Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:300601 截至 2025 年 7 月的收入和支出明細</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Dive into all 741 of the Global High Growth Tech and AI Stocks we have identified here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>深入瞭解我們識別的 741 只全球高增長科技和人工智能股票。</li>
<li>投資了這些股票中的任何一隻？通過 Simply Wall St 簡化您的投資組合管理，並隨時獲取有關您股票的關鍵更新提醒。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受跨越每個大洲的市場情報的免費訪問。</li>
</ul>
</div><h2>Seeking Other Investments?</h2>
<div class="lb-trans"><h2>尋找其他投資？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力可觀但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

探討全球市場中的三隻高增長科技股票